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Specific antisera were raised against synthetic peptide fragments of bovine chromogranin A. The soluble proteins of 
bovine chromaffin granules were subjected to two-dimensional immunoblotting with these antisera. The endogenous 
breakdown products of chromogranin A gave distinct patterns of immunostaining which enabled us to correlate these 
peptides with defined regions of the chromogranin A molecule. The results establish that within chromaffin granules 
degradation of chromogranin A by the endogenous proteases can start either at the C- or the N-terminal site. 
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1. INTRODUCTION 
Chromogranin A is a protein originally isolated 
from chromaffin granules of bovine adrenal 
medulla [ 11. More recently it was discovered that 
this protein had a widespread distribution in en- 
docrine organs [l] and in brain [2,3]. 
Chromogranin A is synthesized as a single propro- 
tein [4,5] which is subsequently processed by en- 
dogenous proteases within chromaffin granules 
[6-81. In mature bovine chromaffin granules 
about 50% of the proprotein has already been pro- 
cessed [ 11. 
In the present study we used antisera against 
peptides present in the amino acid sequence [9,10] 
of chromogranin A in order to characterize the en- 
dogenous breakdown products of chromogranin 
A. This approach was chosen since most of these 
peptides are so closely related in size and charge 
that a separation and subsequent sequencing ap- 
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peared difficult or even impossible. The results in- 
dicate that in contrast to proenkephalin, another 
peptide present in chromaffin granules [l 11, pro- 
teolytic processing of chromogranin A can occur at 
cleavage points close to either the N- or the C- 
terminus. 
2. MATERIALS AND METHODS 
Soluble proteins from bovine chromaffin granules, isolated 
as described [12], were separated by two-dimensional non- 
equilibrium pH gradient electrophoresis [12] followed by im- 
munoblotting with various antisera [12]. Biolytes (pH range 
4-6) were from Bio-Rad, Vienna. 
Seven peptides present in the amino acid sequence of 
chromogranin A [9,10] were synthesized by standard solid 
phase tBOC chemistry and purified by reverse phase HPLC. 
These peptides were: LE40 (Ch AI-.+o), HE35 (Ch A79-II)), 
G&23 (Ch A272.e294, WE14 (Ch A316-329), LL33 (Ch 
A332-360, GE25 (Ch A367-391) and PL26 (Ch &O&428). The ab- 
breviations indicate the N- and C-terminus by the one-letter 
code plus the total number of amino acids. WE14 and GGa23 
were conjugated to bovine thyroglobulin via carbodiimide 
(Smith, P. and Eiden, L.E., in preparation). LE40 was con- 
jugated to soybean trypsin inhibitor at sulfhydryl groups [ 131 in 
order to leave the N-terminus free. The other peptides were 
coupled through amino groups using the benzoquinone pro- 
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cedure 1141. The conjugates were used to establish peptide an- 
tisera in New Zealand white rabbits with a standard 
immunization protocol. The working dilution for the antisera in 
immunoblots was 1: 200. Experiments with chondroitinase 
ABC (Sigma, Munich) incubation were performed as described 
[I51. 
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Fig. 1. Immunoblots with antisera against peptides present in chromogranin A. Soluble proteins (4Opg) were subjected to two- 
dimensional electrophoresis followed by Coomassie blue staining and immunoblotting with antisera against several peptides as 
indicated. Chromogranin A is numbered with 1, the endogenous breakdown products with consecutive numbers. Spot 4 consists of 
two peptides (a and b) which focus closely together. Antiserum aLE40 reacts only with 4a, but not with 4b. When such an immunoblot 
is subsequently labeled with aHE spot 4b is also stained (see inset in aLE40) demonstrating the distinct properties of 4a and 4b. 
PG stands for the proteoglycan form of chromogranin A and for other corresponding breakdown products (PGt, PGz). When the 
soluble proteins are treated with chondroitinase ABC before immunoblotting the PG-spots disappear (see insets for aGGa23 and 
aWE14). In the immunoblot for LL33 spots 2, 4b and 5 were rather weak not allowing photographic reproduction. 
3. RESULTS 
The soluble proteins of bovine chromaffin 
granules were subjected to two-dimensional elec- 
trophoresis followed by immunoblotting. In the 
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Coomassie blue-stained pattern shown in fig. 1 the 
protein spots reacting with antisera against pep- 
tides present in chromogranin A [l] are con- 
secutively numbered. In addition to chromogranin 
A, representing the proprotein [l], several addi- 
tional spots, i.e. the endogenous breakdown 
products, are present. The reactivity of these spots 
with antisera raised against specific peptides of the 
chromogranin A sequence (fig.2) is shown in fig. 1. 
It can be clearly seen that each antiserum gives a 
distinct pattern, which was well reproducible. In 
fig.2 the reactivity of the various protein spots is 
used to compute the most likely amino acid se- 
quence representing these protein spots, In addi- 
tion to chromogranin A antisera against this 
protein stain an additionaI spot of larger molecular 
size (PG in fig.1) which has been identified as a 
proteoglycan of chromogranin A [ 1% 171. Staining 
of this PG-chromogranin by antisera is variable 
(see fig.1). However, two apparent breakdown 
products of this PG are staining strongly by the an- 
tiserum against peptides WE14 and GGa23. Their 
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Fig.2. Chromogranin A-immunoreactive proteins in bovine 
chromaffin granules. The amino acid sequence of 
chromogranin A is schematically presented together with the 
various peptides (used for raising antisera) drawn in the proper 
positions. Possible sites of tryptic cleavage (pairs of basic amino 
acids) are indicated by arrows. The peptides 2-9 are numbered 
as indicated in the Coomassie blue stain given in fig.1. Their 
peptide composition was computed from the immunoblotting 
results with specific antisera (see fig.1). In some cases where 
stretches of peptides, for which no antisera were available, are 
present in an endposition (peptides 5, 6) the length of the 
peptide could only be deduced from the molecular size of the 
peptides derived from electrophoresis results. A broken line in 
the figure indicates that the exact endpoint of the peptide is not 
known. 
proteoglycan nature was identified by chon- 
droitinase ABC digestion which degrades PG and 
these two additional spots (see insets in fig.1 for 
aGGa23 and aWE14). 
4. DISCUSSION 
Proenkephalin is processed in chromaffin 
granules starting from the C-terminal site [ 11,181. 
Thus all large enkephalin-containing peptides 
generated in these organelles contain syn- 
enkephalin, i.e. the peptide on the end of the N- 
terminal site [ 181, whereas in brain processing can 
occur from the N-terminus of the proenkephalin 
molecule [ 191. Therefore, for adrenal chromogra- 
nin A, we expected [20] to find processing from the 
C-terminal site of the molecule and in fact peptides 
2, 3 and 4a (in fig-l) are due to processing from 
this site. However, the results for peptide 4b can 
only be explained by a processing from the N- 
terminal site and in fact peptide 9 was found to be 
the peptide removed by such a cleavage (see fig.2). 
This peptide was previously not recognized as a 
product of chromogranin A processing [1,7], 
which was partly due to its more alkaline PI, which 
is quite different from all the other 
chromogranins. This pI can now be explained 
rather nicely by the amino acid composition of the 
sequence of the N-terminus of chromogranin A. In 
contrast to total chromogranin A the ratio of 
acidic to basic amino acids of the N-terminus 
(chromogranin Al-76) is relatively low (1 .l versus 
1.6). Thus our results clearly establish that 
chromogranin A processing can start at two sites. 
Apparently cleavage at the N-terminal site is a ma- 
jor pathway of processing, since peptide 4b formed 
by such cleavage represents the major degradation 
product (see fig. 1). This phenomenon is apparently 
not confined to the adrenal medulla, but also oc- 
curs in the pituitary where peptide 9 was found to 
be present (Fischer-Colbrie, R., unpublished). 
The exact cleavage points have not been 
established in the present study; however, for pro- 
enkephalin processing a trypsin-like enzyme is in- 
volved and such an enzyme activity has been 
described in chromaffin granules [21]. Our results 
are consistent with the action of such an enzyme. 
Since, however, the exact length of several of these 
peptides cannot be ascertained by our method, 
cleavage may also occur at other sites. 
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We have now established that the processing of 
chromogranin A can start both at the C- or N- 
terminal site which is in contrast to adrenal pro- 
enkephalin. This may be due to differences in the 
molecular properties of chromogranin A and pro- 
enkephalin. Chromogranin A has a random coil 
structure 1221, a trypsin-like enzyme may therefore 
find access to several regions of the intact 
molecule. However, our results may also be ex- 
plained by different proteases for processing of 
chromogranin A and proenkephalin in adrenal 
medulla. Alternatively one might suggest hat the 
co-storage of chromogranin A with neuropeptide 
hormones dictates the processing of these peptides. 
This hypothesis is consistent with the data of 
Seidah et al. [23] that chromogranin A inhibits 
proenkephalin processing in vitro. It will be in- 
teresting to determine whether the presence or 
absence of chromogranin A in secretory organelles 
determines C- or N-terminal processing of pro- 
enkephalin. These questions, however, can only be 
answered when the enzymes controlling these pro- 
cesses have been isolated. 
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